Founded in 2018, 键嘉机器人 develops orthopedic surgical robots and has positioned itself as a domestic leader in hip joint replacement robotics. Its first domestically developed product, ARTHROBOT, targets both acetabular and femoral procedures and claims to control final surgical error within 1 mm and angle deviation within 1°. The company emphasizes a医工结合 (clinical-engineering) team with core technology origins linked to Tsinghua University and the national 863 program. Under its current strategy, 键嘉 focuses on close clinical collaboration to solve pain points of manual joint replacement, reduce surgeon learning curves, and lower intraoperative radiation exposure. The company plans to use new funding to accelerate clinical trials, registration, and new product R&D and to build a surgical-robot platform business offering overall orthopedic solutions and personalized treatments. Prior financing includes an A round in early 2020 of several tens of millions RMB from BV Baidu Ventures.

Total raised

$15M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2020